Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imipenem.

W C Hellinger1, N S Brewer

  • 1Division of Infectious Diseases and Internal Medicine, Mayo Clinic Jacksonville, Florida.

Mayo Clinic Proceedings
|October 1, 1991
PubMed
Summary
This summary is machine-generated.

Imipenem, a novel carbapenem antibiotic, offers broad-spectrum activity against many bacteria, including difficult-to-treat gram-negative pathogens. Careful use is advised to prevent resistance and manage potential side effects like seizures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-derived tuberculosis (TB) infection in lung transplant despite following recommended algorithm.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same author

Evaluation of risk factors for cytomegalovirus infection and disease occurring within 1 year of liver transplantation in high-risk patients.

Transplant infectious disease : an official journal of the Transplantation Society·2013
Same author

Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy.

Transplant infectious disease : an official journal of the Transplantation Society·2013
Same author

Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Association of surgeon with surgical site infection after liver transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Healthcare-associated hepatitis C virus transmission among patients in an abdominal organ transplant center.

Transplant infectious disease : an official journal of the Transplantation Society·2009
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Imipenem represents the first carbapenem antibiotic, a new class of beta-lactam antimicrobials.
  • It exhibits the broadest spectrum of antibacterial activity among systemically available antibiotics for human use.

Purpose of the Study:

  • To review the clinical profile of imipenem, including its antibacterial spectrum, dosing, and toxicity.
  • To provide guidance on appropriate use in treating specific bacterial infections.

Main Methods:

  • Review of existing literature on imipenem's pharmacological and clinical properties.
  • Analysis of its activity against various bacterial pathogens, including common nosocomial isolates.

Main Results:

Related Experiment Videos

  • Imipenem is active against streptococci, methicillin-sensitive staphylococci, Neisseria, Haemophilus, anaerobes, and aerobic gram-negative pathogens like Pseudomonas.
  • Resistance can emerge during P. aeruginosa treatment; P. maltophilia and P. cepacia are typically resistant.
  • It also shows inhibitory activity against enterococci, similar to penicillins.

Conclusions:

  • Imipenem is indicated for mixed bacterial infections and infections caused by resistant aerobic gram-negative bacteria unresponsive to other beta-lactams.
  • Judicious use is crucial to avoid unnecessary toxicity and prevent the spread of imipenem resistance.